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Abstract
Introduction: Inhibition of gamma-secretase presents a direct target for lowering Ab production in the brain as a
therapy for Alzheimer’s disease (AD). However, gamma-secretase is known to process multiple substrates in
addition to amyloid precursor protein (APP), most notably Notch, which has limited clinical development of
inhibitors targeting this enzyme. It has been postulated that APP substrate selective inhibitors of gamma-secretase
would be preferable to non-selective inhibitors from a safety perspective for AD therapy.
Methods: In vitro assays monitoring inhibitor potencies at APP g-site cleavage (equivalent to Ab40), and Notch ε-
site cleavage, in conjunction with a single cell assay to simultaneously monitor selectivity for inhibition of Ab
production vs. Notch signaling were developed to discover APP selective gamma-secretase inhibitors. In vivo
efficacy for acute reduction of brain Ab was determined in the PDAPP transgene model of AD, as well as in wild-
type FVB strain mice. In vivo selectivity was determined following seven days x twice per day (b.i.d.) treatment with
15 mg/kg/dose to 1,000 mg/kg/dose ELN475516, and monitoring brain Ab reduction vs. Notch signaling endpoints
in periphery.
Results: The APP selective gamma-secretase inhibitors ELN318463 and ELN475516 reported here behave as classic
gamma-secretase inhibitors, demonstrate 75- to 120-fold selectivity for inhibiting Ab production compared with
Notch signaling in cells, and displace an active site directed inhibitor at very high concentrations only in the
presence of substrate. ELN318463 demonstrated discordant efficacy for reduction of brain Ab in the PDAPP
compared with wild-type FVB, not observed with ELN475516. Improved in vivo safety of ELN475516 was
demonstrated in the 7d repeat dose study in wild-type mice, where a 33% reduction of brain Ab was observed in
mice terminated three hours post last dose at the lowest dose of inhibitor tested. No overt in-life or post-mortem
indications of systemic toxicity, nor RNA and histological end-points indicative of toxicity attributable to inhibition
of Notch signaling were observed at any dose tested.
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Introduction
The principal pathological features of Alzheimer’s disease
(AD), comprised of neurofibrilary tangles and amyloid
plaques, are posited by the amyloid cascade hypothesis
[1-3] to be pivotal in the clinical manifestations (impaired
memory and cognition, dementia) of the disease. Current
marketed therapies for AD offer palliative cognitive bene-
fits with little to no impact on the underlying pathology,
or on long-term disease progression. Effective treatments
for AD that address the underlying disease represent a
major unmet medical need.
Immunotherapy targeting Ab has been demonstrated
to modify amyloid [4,5] as well as tau related endpoints
[6,7] of AD pathology in pre-clinical models, as well as
human clinical trials, and is currently in advanced clini-
cal trials for potential treatment of mild to moderate
AD [8,9]. Orally bioavailable small molecule therapeutics
offer the desirable attributes of convenient administra-
tion combined with in-home use for chronic therapy of
AD, and as such, are anticipated to fill an unmet need
in the emerging landscape of next generation AD
therapeutics.
Pharmacological inhibition of gamma-secretase in vivo
is a well-documented small molecule target for lowering
brain, CSF, and plasma Ab peptide [10-18], and impact-
ing AD pathology [14,19-22]. Gamma-secretase inhibi-
tors (GSIs) have also shown benefits on presumed
correlates of memory in AD transgene models under
acute [23], as well as, chronic treatment paradigms [24].
Consequently, gamma-secretase has been the target of
ongoing medicinal chemistry efforts to discover thera-
peutics for treatment of AD [25-27]. However, inhibition
of Notch processing by non-selective GSI’sm a n i f e s t si n
dysregulated cellular homeostasis and non-target organ
side effects, for example, goblet cell hyperplasia in the
gastrointestinal tract [28-30], that translate to clinical
observations [31-33], and present challenges for clinical
development of first generation GSI’s [34]. Support for
the observation that pharmacological effects of GSI’so n
cellular homeostasis in the gastro-intestinal tract are
due to dysregulation of Notch pathway derives from
observations with genetic knock-out [35-38] as well as
gain of function mouse models [39] of Notch pathway
genes.
Approaches to managing gastro-intestinal side effects
of first generation GSIs via intermittent dosing [40,41]
or glucocorticoid therapy [42] have been demonstrated
in pre-clinical models. Additional efforts targeting
gamma-secretase for AD therapy have been influenced
by gamma-secretase cleavage site modulating properties
of certain NSAIDS [43-45], and APP substrate selective/
Notch sparing GSIs (this report, [46-48]) as a means
toward mitigating inhibition of Notch signaling. Clinical
development of the most advanced NSAID based
gamma-secretase modulator, tarenflurbil, was discontin-
ued due to lack of efficacy in P3 clinical trial [49,50],
however, second generation candidates are progressing
through both clinical [51] as well as preclinical stages of
development [52-55]. Additionally, a nucleotide binding
site on presenilin has also been reported to inhibit Ab
while sparing Notch [56-58], and offers another avenue
under investigation for the next generation of gamma-
secretase inhibitors.
The pharmacological and genetic evidence cited
above validate gamma-secretase as a target for lower-
ing Ab production as well as non-target organ side
effects due to inhibition of Notch signaling. Together,
the observations support the hypothesis that APP
selective gamma-secretase inhibitors offer one
approach toward potentially safer gamma secretase
targeted therapeutics for AD. Toward that end, we
report here the discovery of novel APP selective inhi-
bitors of gamma-secretase discovered from a high
throughput screen of a chemical library enabled by
novel assays for comparing APP and Notch cleavage
by gamma-secretase. We confirmed that the improved
in vitro selectivity of our lead compound, ELN475516
translates into improved in vivo safety in a mouse
model that is sensitive to histological and molecular
end-points associated with inhibition of Notch
signaling.
Materials and methods
Compounds
ELN46719 is the 2-hydroxy-valeric acid amide analog of
LY411575 (where LY411575 is the 3,5-difluoro-mandelic
acid amide) (US Patent No 6,541,466). ELN318463 was
described by Zhao et al. [59], and ELN475516 has been
described as compound 11a by Mattson et al. [60].
Antibodies and substrates
Notch intracellular domain (NICD) neo-epitope monoclo-
nal antibody (mAb) 9F3 was generated by immunizing
mice with VLLSRGGC (corresponding to amino-terminus
of human NICD, residues 1755 to 1759 in full length
Notch) coupled to maleimide activated sheep anti-mouse
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were fused with mouse myeloma cells. Hybridomas were
screened against VLLSRGGC and counter screened
against GCGVLLSR. Monoclonal antibody 9F3 only recog-
nized VLLSRGGC peptide. The specificity of 9F3 for
recognition of the amino-terminal neoepitope of NICD
product, revealed from in vitro digestion of NotchΔE sub-
strate by gamma-secretase enzyme, but not the uncleaved
NotchΔE substrate, was confirmed by Western blot assay.
The sequence of this epitope is conserved between human
and mouse Notch1.
E. coli expressed MBP-APPc125sw fusion protein sub-
strate [61], was purified by amylose affinity chromato-
graphy per manufacturer’s protocol (New England
Biolabs, Ipswich, Massachusetts, USA) and stored at
-40°C as 2 mg/mL stock in 3 M guanidine-HCl, 1% Tri-
ton-X100, 20 mM Tris, (pH 7.5) until use.
NotchΔEΔCs u b s t r a t e :A Notch fusion protein was
constructed so as to be analogous to the APP C99
fragment as described [62]. Specifically, the Notch
fusion protein is comprised of 99 amino-acids flanking
the trans-membrane domain of mouse Notch1, acces-
sion (Genbank: Z11886). The amino-terminus of the
fusion protein begins at residue #1711 of mouse
Notch (numbered from initiator methionine residue),
and extends carboxy-terminal to residue #1809, fol-
lowed by in-frame fusion with HA epitope tag and six
histidine residues prior to the stop codon. The two
carboxy-terminal epitope tags are separated by an “LE”
di-peptide spacer. The epitope tags were incorporated
to facilitate ELISA detection of the NICD cleavage
product using anti-HA antibody, and purification of
the fusion protein substrate from E.coli lysates using
nickel column affinity chromatography, respectively.
Following overnight expression of the fusion protein
in E.coli, the substrate is purified on a nickel-sephar-
ose column from lysates. Purity of the 16 kD Notch
fusion protein substrate eluted from the nickel-affinity
column is confirmed by SDS-PAGE. Fractions contain-
ing the desired protein were pooled, adjusted to 0.5 to
0.6 mg/mL final concentration in 3M Guanidine-HCl,
0.1% Triton X-100 with 20 mM DTT, and stored at
-80°C in aliquots until use in the enzyme reaction.
This protein is not stable over long periods, and will
aggregate even in the above storage buffer at -80°C.
Hence, a new batch is prepared every three months to
ensure assay quality. The substrate is desalted over a
NAP-25 column immediately prior to use, protein
concentration is determined by BCA assay (Pierce,
Rockford, Illinois, USA), and diluted 20X for incuba-
tion with enzyme.
NICD ELISA standard: A human NICD standard was
produced as a fusion protein from a construct in the
bacterial expression vector pCal-kc (Invitrogen,
Carlsbad, California, USA). The expression construct
was modified to encode an initiating methionine fol-
lowed by an enterokinase cleavage at the N-terminus,
fused in frame to the gamma-secretase product NICD
(Met-EK-NICD, where NICD comprises residues 1755
to 1875 of human Notch1, numbering from the initiator
methionine), an 8 residue spacer comprising the
sequence PAAAAAA, and an HA epitope tag fused in
frame with vector derived kemptide peptide, thrombin
cleavage site and carboxy-terminal calmodulin binding
peptide. The fusion protein was produced in E.coli,a f f i -
nity purified using a calmodulin affinity resin and
assayed for protein concentration. The protein was then
cleaved with enterokinase in order to produce the free
N-terminus of the NICD product. The enterokinase
cleaved protein was separated by SDS-PAGE on a 12%
Tris-glycine gel. Enterokinase cleavage products are
detected by Western blotting using an antibody against
the HA-tag. Densitometry was used to measure the effi-
ciency of the enterokinase cleavage. The estimated con-
centration of enterokinase cleaved NICD standard is
calculated (% of NICD/total HA-reactive protein). The
standard was stored at -40°C. On the day of each assay,
an aliquot of the NICD standard is serially diluted 1:1 in
casein diluent to generate a standard curve with 0 to
200 ng/mL NICD.
Enzyme preparation and in vitro assays for recombinant
APP and Notch substrate cleavage
An enriched detergent solubilized gamma-secretase
enzyme preparation from IMR-32 neuroblastoma cells
was obtained by membrane fractionation of crude
homogenates using ultracentrifugation, followed by lec-
tin affinity chromatography. Briefly, a 100,000 g mem-
b r a n ep e l l e to fp o s tn u c l e a rs u p e r a n t a n tf r o mI M R 3 2
frozen cell pellets was homogenized in buffer (250 mM
sucrose, 10 mM HEPES (pH 7.5), 1 mM MgCl2, 0.2 mM
CaCl2 + protease inhibitors, 5 mL/g cell pellet), resus-
pended in an equal volume of hypotonic buffer (homo-
genization buffer minus sucrose), subjected to freeze
thaw (dry-ice, 37°C water bath), and re-centrifuged at
100,000 x g for 20 minutes at 4°C. The membrane pellet
was snap frozen on dry ice, and stored at -80°C until
extraction. Thawed membranes were washed in 1 M
carbonate buffer (1 M Na2CO3,1m MM g C l 2,0 . 2m M
CaCl2) at 4°C for 15 minutes, centrifuged 100,000 X g
as explained above, and resuspended in hypotonic wash
buffer. Washed membrane pellets were resuspended in
0.5X final volume of solubilization buffer (10 mM CHES
pH 9.5, 50 mM NaCl, 1 mM MgCl2, 0.2 mM CaCl2 +
protease inhibitors, minus pepstatin) and extracted in
detergent containing 1.49 mg/mL BigCHAP (ICN),
diluted fresh 1:10 from 50X stock (149 mg/mL in H2O),
at 4°C for 1.5 h. Detergent extracts were centrifuged at
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taining solubilized gamma-secretase aspirated for WGA
chromatography. Peak eluate fractions were combined,
a n ds t o r e di n1 0m MH e p e s ,p H7 . 5 ,1MN - a c e t y l - D -
glucosamine, 1 mM MgCl2, 0.2 mM CaCl2,0 . 6m g / m L
TypeV brain extract (Sigma, S t .L o u i s ,M i s s o u r i ,U S A ) ,
5.6 mg/mL BigCHAP.
In vitro assay for cleavage of recombinant fusion protein
substrates by partially purified gamma-secretase enzyme
from IMR-32 cells
The in vitro gamma-secretase assay was designed to
measure the specific proteolytic cleavage of an APP sub-
strate (MBP-APPc125Sw fusion protein) at the Ab40
site, or cleavage of Notch fusion protein at the Notch
ε-site (corresponding to N-terminus of NICD). The sub-
strates were incubated in separate reactions, in triplicate,
with an enriched preparation of the enzyme from IMR-
32 cells, and the amount of specific product formed was
measured using a sandwich ELISA comprised of an
Ab40-specific capture antibody, 2G3, and a biotinylated
Ab17-28 reporter antibody, 6H9 for APP substrate, or
Notch ε- s i t es p e c i f i ca n t i b o d y9 F 3 ,s p e c i f i cf o rt h e
amino-terminus of the NICD (beginning at V1755 of
human Notch protein), as capture and anti-HA epitope
tag antibody as the reporter for Notch substrate. Incuba-
t i o no ft r i p l i c a t er e a c t i o n si nt h ep r e s e n c eo far a n g eo f
inhibitor concentrations enabled determination of a
dose-response for enzyme inhibition by the test com-
pound and calculation of an IC50 value. Data analysis
was performed using XLfit software package (IDBS Soft-
ware Inc. Alalmeda, California, USA).
Recombinant APP or Notch fusion protein substrates
(purified as described above) were incubated in reaction
b u f f e r( 5 0m MM E S ,p H6 . 0 ,4 0 0μg/mL Type-V phos-
pholipid, 5.6 mg/mL BigCHAP, 4 mM DTT, 0.02% TX-
100) at 20 μg/mL or 30 ug/mL, respectively, with
approximately 0.4 mg/mL enzyme preparation (1:100 to
1:250 dilution, depending upon batch to batch variation
of specific activity) for 2 h at 37°C in the presence of
protease inhibitors (1 mM 1,10-phenanthroline, 5 ug/
mL E64, and 5 ug/mL leupeptin) in the presence of a
concentration range of test inhibitor compounds. Reac-
tions were quenched with 0.1% SDS for 10 minutes at
room temperature, followed by addition of equal volume
of specimen diluent (1.5 mM NaH2PO4
.H2O, 8 mM
Na2HPO4
.7H2O, 8 mM NaN3, 150 mM NaCl, 0.05%
(volume/volume) Triton X-405 0.6% (w/v) BSA, (globu-
lin free).
ELISA detection of Ab40 cleavage product
The diluted enzyme reaction mixture was transferred to
antibody 2G3-coated Immulon plates (specific for Ab40
carboxy-terminal neo-epitope) and incubated overnight
along with Ab1 to 40 standards (32 to 2,000 pg/mL in
Specimen diluent). The ELISA was developed the fol-
lowing day by sequential one hour incubations with bio-
tinylated 6H9 reporter antibody (Elan, Ab 17-28
specific, 0.25 μg/mL) for one hour at room temperature,
and Streptavidin-Alkaline Phosphatase Conjugate
(Roche Molecular Biochemicals, Catalog No. 1089 161,
Indianapolis, Indiana, USA), 1:1,000 in specimen diluent,
one hour room temperature. The ELISA was developed
using fluorescent alkaline phosphatase substrate, and the
plate is read at 360 nm excitation/460 nm emission,
gain approximately 50, in a CytoFluor 4000 (Applied
Biosystems, Foster City, California, USA). The plates
were washed 3X each with Tris-buffered saline/0.05%
Tween-20 between incubations with reporter antibody,
detecting antibody, and fluorescent substrate.
ELISA detection of NICD product
Quenched in vitro gamma/Notch reactions were diluted
1:1 with casein diluent buffer containing 500 mM NaCl,
0.02% TritonX-100 and plated onto Notch ε-cleavage
site specific neoepitope mAb 9F3 (specific for the
amino-terminus of NICD, beginning at V1755 of human
Notch) coated immulon plates, for capture of the NICD
reaction product overnight at 4°C. NICD standards, pre-
pared as described above, were serially diluted 2X over a
concentration range from a starting concentration of
50 ng/mL for establishing a standard curve. The NICD
reaction product and standards captured on the plate
are detected with biotinylated-HA antibody (1 μg/mL
final, Roche Cat# 1666851), followed by alkaline phos-
phatase conjugated streptavidin (diluted 1,000X from
stock, Roche Cat# 1089161). The plate was washed
between each incubation step with Tris-buffered saline
containing 0.1% Tween-20. The alkaline phosphatase
reaction product is detected by incubation with 100 μl/
well Fluorescent Substrate A for 15 minutes at room
temperature, and detected using Cytofluor plate reader
at 360 nm excitation, 460 nm emission.
Dual assay for simultaneous inhibition of Ab and Notch
signaling in cells
In order to test the potency and selectivity of gamma-
secretase inhibitors against two substrates (APP and
Notch) simultaneously, we developed a dual-assay CHO
cell line stably expressing APPSw, a Notch substrate
lacking the ecto-domain, and a Notch responsive Luci-
ferase reporter gene. As a first step, CHO cells stably
over-expressing the APPsw were established. These cells
secrete high levels of Ab peptide into the conditioned
media from endogenous b-a n dg-secretase enzyme
activity. A Notch intracellular domain responsive repor-
ter gene, and the constitutive gamma-secretase Notch
substrate, NotchΔE, were stably introduced into CHOsw
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bly transfected to express a NICD responsive luciferase
reporter gene construct (pGL2-CBF-Luc) [63]. Numer-
ous stable clones (SCH clones), were identified which
displayed GSI sensitive Notch signaling upon transient
expression with ZEDN, a rat NotchΔEe x p r e s s i o nc o n -
struct [64]. Three clones exhibiting highest signal to
noise NICD responsive luciferase activity (SCH-32,
SCH-33 and SCH-54) were selected as the hosts for
subsequent stable expression of NotchΔE by transfection
with pIRES-ZEDN1in the final step of generating a dual-
assay cell line. Stable cell lines expressing rat NotchΔE
were identified following transfection of the rat
NotchΔE construct by selection with media supplemen-
ted with the g-secretase inhibitor ELN-46719 (to sup-
press Notch/NICD toxicity), G418 (0.5 mg/mL),
hygromycin (1 mg/mL) and puromycin (2.5 μg/mL).
Antibiotic-resistant colonies (named SNC clones for the
dual-assay components: APPsw/NotchΔE/CBF) were
isolated and expanded for characterization of Ab secre-
tion and NICD responsive reporter gene activity (that is,
luciferase signal in the presence versus absence of
ELN46719). Based on optimal Ab secretion, and highest
signal/background of reporter gene activity, a clone
designated as SNC-204B8 was selected as the dual-assay
stable line for subsequent profiling of APP selective
g-secretase inhibitors. Activity and selectivity of com-
pounds for inhibition of Ab production versus Notch
signaling was determined by plating the cells in 96-well
plates in media lacking ELN46719 overnight. The fol-
lowing day, media was replaced and supplemented one
hour later with an equal volume of additional media
containing test compounds over a concentration range 0
nM to 40,000 nM (final, in 10X dilution increments).
The cells were treated with compounds overnight at
37°C. The following day (Day 3), conditioned media was
aspirated from cells for determination of Ab1-x levels by
ELISA [65], and cells were lysed for determination of
Notch signaling by luciferase reporter gene activity (Pro-
mega, Madison, Wisconsin, USA) per manufacturers
protocol.
Analysis of APP metabolites from inhibitor treated cells
APP metabolites were analyzed by Western blot of SDS-
PAGE fractionated cell extracts and media derived from
HEK293 cells stably expressing APPsw mutation follow-
ing overnight treatment with different gamma-secretase
inhibitors. Equal concentrations of protein (BioRad, Her-
cules, California, USA) from cell extracts were loaded for
Western blot analysis. As reference GSI’sw eu s e d
LY411575, and the Merck active site directed isostere
L-685458 for comparison with ELN-318463. Compounds
were tested at two doses, approximately 1 X ED50 and
approximately 10 X ED50 values in the SNC assay.
Different anti-APP antibodies were used to test the com-
pounds for effects on Ab, total secreted APP, b-sAPP,
full length-APP and APP CTFs (C-terminal fragments of
APP resulting from a- and b-secretase cleavage) as noted
below. Secreted Ab in the conditioned media was quanti-
fied by ELISA using 2G3/3D6, which detects Ab (1 to
40). The full length APP and CTF Western blots were
probed with anti-APP-c-terminal specific antibody
(Sigma). Western blots of the conditioned medium sam-
ples (normalized for differences in cell density by protein
concentration of the cell extracts) were probed with anti-
body 8E5 [66] which recognizes total secreted APP, and
192sw [67,68] which recognizes the carboxy-terminus of
secreted APP arising from BACE cleavage of the APPsw
overexpressed in these HEK293 cells.
Binding site studies
A displacement assay employing affinity capture of
gamma-secretase complex with a biotinylated analog of
active site isostere L685,458 [69] was developed to char-
acterize binding site of the APP selective sulfonamides.
PS1 and Nicastrin (Nct) Western blots were employed
as readout for association of the gamma-secretase com-
plex with the biotinylated probe. Displacement of the
active site isostere by test compounds resulted in low-
ered intensity of PS1 and Nct bands on the immuno-
blots. The biotinylated active-site isostere inhibited APP
cleavage in our gammaAPP assay with an IC50 = 11
nM. The results with L685,458 and LY-411575 were
repeated three times, while the result observed with
ELN318463 was replicated with a close structural analog
of ELN318463 (not shown). The result shown with
ELN475516 is from one of two independent replicates.
Briefly, in the displacement assay a WGA affinity puri-
fied solubilized membrane preparation containing
enriched gamma-secretase enzyme (from CHO S1 cells
[70] prepared as described above), is diluted in incuba-
tion buffer under gammaAPP reaction conditions, and
pre-cleared (30 minutes at room temperature) with
streptavidin-sepharose resin (Amersham/GE Healthcare,
Piscataway, New Jersey, USA) in order to remove endo-
genous biotinylated proteins and reduce nonspecific
background signal. Biotinylated analog at 50 nM is
added to pre-cleared extract with or without competing
test compounds at different concentrations, and incu-
bated at 37°C for two hours. Streptavidin-sepharose is
then added, and the mixtures are incubated at RT for
30 minutes. Following capture, the beads are centrifuged
briefly (two minutes at 10,000 g) and washed twice with
the incubation buffer, followed by Western blot analysis
(Immobilon membranes, Millipore, Billerica, Massachu-
setts, USA) for PS1 NTF (antibody 1563, Chemicon,
Millipore Bioscience Research Reagents, Temecula, Cali-
fornia, USA) and Nicastrin (antibody N1660, Sigma,
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streptavidin resin through the biotinylated compound.
The samples are run on 26-well 10% to 20% acrylamide
Tris-HCl gels (Criterion, BioRad), alongside serially
diluted affinity captured enzyme samples from the same
experiment (minus competing test compound) to pro-
vide a standard curve of on each gel for quantitation
purposes. The PS1 and Nicastrin signals were detected
by horse-radish peroxidase labeled secondary antibody
followed by ECL chemiluminesence (Amersham) and
the images were quantified by densitometry. The relative
amount of PS or Nicastin remaining associated with affi-
nity ligand in the unknown samples is calculated from
the standard curve, and displacement of the biotinylated
compound is reported as percentage of the protein sig-
nal in DMSO vehicle control samples. Binding assays in
the presence of substrate were performed exactly as
described above with the inclusion of 20 μg/ml
(approximately 1 Km) of MBP-APPc125 recombinant
fusion protein [61]. Preliminary experiments (not
shown) indicated that under these conditions, we are
able to capture >90% of enzyme complex in the mix,
and that >90% of captured complex is competed by co-
incubation of the binding mix with 10 μM L-685,458.
Acute reduction of brain Ab in FVB and PDAPP mice
All experiments were approved by the Institutional Ani-
mal Care and Use Committee (IACUC) of Elan Pharma-
ceuticals and conducted in accordance with its
guidelines. Female, two- to three-month old, FVB/N
mice were purchased from Taconic (Oxnard California,
U S A ) .M i c ew e r eh o u s e df o u rt of i v et oac a g eo na
12-hour light/dark schedule. Water and food were avail-
able ad libitum. FVB mice were treated orally with a
single dose (n = 7/dose) of compound as indicated in
the associated Figures. The test articles were formulated
at various concentrations in a 10% Solutol
®/water vehi-
cle (BASF Corp, Florham Park, New Jersey, USA) and
dosed at 5 mL/kg via oral gavage. Control animals were
dosed with vehicle. Animals were sacrificed at three
hours post dose, unless indicated otherwise. Cortical
brain samples were collected, frozen on dry ice and
stored at -80°C until homogenization for determination
of Ab and compound levels. Thymus was collected, fro-
zen in liquid nitrogen, stored at -80°C for analysis of
Hes1 levels. Blood samples were collected by cardiac
puncture, processed to plasma, frozen on dry ice and
stored at -80°C until determination of compound levels
by LC-MS-MS. Statistical analysis of data was performed
using one-way ANOVA followed by Dunnett’s.
Repeat dose mouse seven-day toxicity study
FVB mice, female, two to three months old, were treated
orally with ELN475516 (15, 30, 100, 300, 600, and 1000
mg/kg/dose) or LY411575 (5 mg/kg/dose) twice per day
(b.i.d.) for seven days (N=5 per treatment group). The
test articles were formulated at various concentrations
in a 10% Solutol
®/water vehicle and dosed at 5 mL/kg
via oral gavage. Control animals were dosed with vehi-
cle. All animals were sacrificed at three hours post last
dose. Cortical brain samples were collected, frozen on
dry ice and stored at -80°C until homogenization for
determination of Ab a n dc o m p o u n dl e v e l s .B l o o dw a s
collected, (via cardiac puncture), processed for CBC, or
processed to plasma and frozen on dry ice and stored at
-80°C until determination of compound levels. Duode-
num and ileum, as well as other tissues, were collected
from each treatment group and fixed in 10% formalin for
histopathology evaluation. Body weight was reported as
percent change from the base line and compared to vehi-
cle control group in the one-way ANOVA Dunnett’s test
for statistical analysis. Relative organ weight was calcu-
lated by the absolute organ weight/body weight. Statisti-
cal analysis was done by Prism software/one-way
ANOVA (and nonparametric) Dunnett’s test for all toxi-
city endpoints. Most endpoints examined were significant
at P < 0.001 except on one parameter which was P < 0.01
and is noted in the appropriate figure legend. Duodenum
and ileum tissues were sectioned and double stained with
H&E (hematoxylin and eosin) plus PAS (periodic acid-
Schiff stain) for histopathologic evaluation.
Endogenous mouse brain Ab ELISA
Cortical brain samples were homogenized in 5 M guani-
dine and Abx-40 was estimated in a sandwich ELISA uti-
lizing the monoclonal antibodies 266 (made against 16
to 28 amino acid sequence of Ab) as the capture, and
2G3 (terminal specific to Ab40) as the reporter. This
assay estimates the concentration of Ab peptides ending
at amino acid 40, without specificity for amino termini
upstream of residue 16. Statistical significance was
determined by ANOVA.
Quantitation of Notch signaling RNA endpoints Hes1/
Math1
Tissues were homogenized in lysis buffer and processed
for total RNA extraction using the QIAGEN Rneasy
96-well plate technology with post-column Dnase treat-
ment. The concentration of RNA per sample was mea-
sured by a RiboGreen RNA quantitation assay
(Invitrogen). Math1 (Atonal homolog) or Hes1 mRNA
levels were quantified by a TaqMan RT-PCR assay and
results were normalized by RNA sample concentration.
The sequences of the primers and probes employed in
the Taqman assay were as follows: Hes1 forward primer:
CGGCTTCAGCGAGTGCAT; Hes1 reverse primer:
CGGTGTTAACGCCCTCACA; Hes1 probe: AAC-
GAGGTGACCCGCTTCCTGTCC. Math1 Forward
Basi et al. Alzheimer's Research & Therapy 2010, 2:36
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Page 6 of 21primer: AGCTGGACGCTTTGCACTTT; Math1 reverse
primer: TCTGTGCCATCATCGCTGTT; Math1 Probe:
5’FAM-CAGCTTTCGAGGACCGGGCCC-TAMRA3’.
All Taqman reagents were acquired from Applied Bio-
systems, Inc., Foster City, CA, USA.
Results
To enable discovery of novel APP selective gamma-
secretase inhibitors, we developed biochemical assays for
substrate cleavage followed by ELISA employing neo-
epitope specific monoclonal antibodies for detection of
products. A detergent solubilized, lectin affinity column
enriched, enzyme preparation derived from IMR-32
neuroblastoma cells was incubated with either recombi-
nant APP-C125, or a Notch fusion protein substrate.
These substrates replicate natural processing of a site
equivalent to the carboxy-terminus of Ab40, or the S3/
ε-site of Notch, respectively, with Michaelis-Menten
kinetics (APP substrate Km= 358 nM, Notch substrate
Km =1 . 5 2μM, Figure S1 in Additional file 1). The pro-
ducts of this reaction were detected and quantified by a
sandwich ELISA employing neo-epitope specific capture
monoclonal antibodies 2G3 (Ab40 specific), or 9F3 (spe-
cific for NICD N-terminus, the C-terminal cleavage pro-
duct derived from NotchΔE in cells [71-73], Figure S2
in Additional file 2), and appropriate detection antibo-
dies as illustrated in Figure 1a. Henceforth, we refer to
this assay measuring gamma-secretase cleavage of APP
fusion protein substrate at Ab40 site as the gamma:APP
assay, and cleavage of NotchΔEΔCs u b s t r a t ea tN o t c h
S3/ε-site as gamma:Notch assay.
A high-throughput screen of a chemical library employ-
ing the gamma:APP assay was conducted to discover
novel inhibitors of gamma-secretase. Hits from the pri-
mary screen (defined as >25% inhibition at 10 μM) were
characterized in secondary assays for dose response,
non-specific inhibition (for example, of non-gamma:APP
enzymatic reactions, assay detection reagents), and
selectivity for inhibition of APP cleavage versus Notch
cleavage by gamma-secretase. A number of hits com-
prising a novel series of p-chlorobenzene-caprolactam
sulfonamide compounds demonstrated concentration
dependent and APP > Notch selective inhibition of
gamma-secretase, as exemplified by ELN158162 , which
displayed an IC50 in gammaAPP assay of 0.65 μM, com-
pared with an IC50 of approximately 25 μMi nt h e
gamma:Notch assay, resulting in a selectivity ratio of
approximately 40 (Figure 1b).
To test for APP-selective inhibition of gamma-
secretase by the screening hits in a cellular context, we
developed a stable CHO cell line co-expressing APPSw,
rat NotchΔE [64], and an NICD responsive CBF-Lucifer-
ase reporter gene [63] (SNC cells), to assay endogenous
gamma-secretase enzyme. Inhibition of secreted Ab was
quantified by an ELISA specific for Ab1-x using condi-
tioned media harvested from cells, and Notch signaling
was detected using a luciferase reporter assay in cellular
lysates from cells treated overnight with a concentration
range of inhibitor compounds. The profile of reference
non-selective gamma-secretase inhibitors compared with
the HTS hit and selective lead compounds in the SNC
dual cell assay corroborated the biochemical enzymatic
assay data, demonstrating APP selective inhibition of
cellular gamma-secretase by the screening hit and select
lead compounds (Table 1).
Biochemical characterization of the inhibitors revealed
they behave as classical GSIs in that they elevate C99
with no effects on sAPPa or sAPPb (Figure 2), and are
equipotent inhibitors of Ab40 and Ab42 (Figure S3 in
Additional file 3). The compounds lowered secreted Ab
in conditioned media at the concentrations tested for
effects on APP metabolites (Figure 2d). Binding site stu-
dies employing biotin labeled active site isostere as affi-
nity ligand for enriched gamma-secretase enzyme
(derived from CHO-S1 cells [70], flow-chart of assay
s h o w ni nF i g u r eS 4i nA d d i t i o n a lf i l e4 )c o n f i r m e d
competitive displacement of affinity ligand by its non-
biotinylated analog L-685,458 (Figure 3a), consistent
with published results [69], as well as by very high con-
centrations of LY411575 (Figure 3b). Specifically, we
observed a 50% displacement of a biotinylated active site
isostere probe by L-685,458 at concentrations approxi-
mately three-fold above its IC50 in the gammaAPP
assay, whereas LY-411575 displaced 50% of biotinylated
active site isostere probe at concentrations 500X to
1,000X above its IC50 value in the gammaAPP assay.
Sulfonamides did not displace biotinylated active site
isostere in competitive binding assays in the absence of
substrate (Figure 3c, d, left half). However, in the pre-
sence of 1 Km (20 μg/ml) MBP-C125 substrate,
ELN318463 and ELN475516 were able to displace the
active site isostere (Figure 3c, d, right half) at an ED50 of
23 μM and 0.14 μM, respectively (data not shown).
These values represent an approximately 2,000X and
67X multiple over the IC50 values of the two com-
pounds in the gammaAPP assay.
In vivo testing of a benzene caprolactam sulfonamide,
ELN318463 [59], possessing favorable oral bioavailabilty
(F = 30% in rat), revealed dose-dependent acute reduc-
tion of brain Ab1-x species in PDAPP mice (Figure 4a).
In contrast, acute reduction of Abx-40 species in non-
transgene FVB mice (Figure 4b) was equivalent at both
doses tested. Reduction of Abx-40 in PDAPP also was
not dose responsive (20% and 25% reduction at 30 mg/
kg and 100 mg/kg, respectively, data not shown). The
l a c ko fad o s er e s p o n s ei nA bx-40 species in PDAPP &
FVB mice compared with Ab1-x species in PDAPP mice
can not be explained by differences in terminal
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Page 7 of 21Figure 1 Schematic illustration of in-vitro assays, and dose response curves of an APP selective gamma-secretase inhibitor.
(a) Recombinant E.coli expressed fusion protein substrates APP MBP-C125Sw (left side, numbering relative to Ab peptide residues, red box) or
mNotch100 substrate (right hand side, numbering relative to initiator methionine residue) were incubated in separate reactions with partially
purified solubilized gamma-secretase enzyme from IMR-32 cells as detailed in methods. The reactions products were analyzed by ELISA using
2G3/6H9 ELISA for AbX-40 for GammaAPP assay product, or the 9F3/anti-HA ELISA for NICD, the GammaNotch assay product. MBP, N-terminal
fusion with maltose binding protein (grey hatched box); TMD, transmembrane domain (blue hatched box); HA, hemagglutnin antigen epitope
tag (green hatched box); HIS-6, hexahistidine residue epitope tag (yellow box). (b) Dose response curve demonstrating APP-selective inhibition
from a representative screening hit ELN158762. The IC50 values for inhibition of APP and Notch substrate cleavage, and selectivity ratio in the
biochemical assays with this compound are reported in Table 1.
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tested, nor by assay differences. Brain levels of
ELN318463 at 30 mg/kg were 0.754 μMi nF V Bb r a i n s
and 0.69 μM in PDAPP brains, and at 100 mg/kg dose
the levels were 2.7 μMi nF V Bb r a i n sa n d1 . 8 7μMi n
PDAPP brains. Discordance between Ab1-40 and Abx-40
in BACE KO or wild-type BACE inhibitor treated mice
has been reported [74]. However, our observations can-
not be explained by differences in assays employed for
measuring Ab1-x vs. Abx-40, as observed by Nishitomi
et al. [74], because both assays used in this study are
insensitive to the Ab P3 fragment (product of alpha-
and gamma-secretase cleavages) by virtue of the capture
antibody employed (see Materials and methods).
Lead optimization toward discovery of more potent
analogs revealed critical requirement for proton donor
in caprolactam ring of benzene-sulfonamides, corrobo-
rated by pyrazole substituted piperidines as scaffold
replacements [60] (Figure S5 in Additional file 5). The
prototype pyrazolylazabicyclo(3.3.1)nonane ELN475516
supported this hypothesis by demonstrating improved
in vitro potency, while retaining APP selectivity of the
caprolactam sulfonamide parent lead series (Table 1).
Furthermore, the novel fused bi-cyclic gamma-secretase
inhibitor demonstrated dose dependent in vivo activity
for acute reduction of cortical Ab1-x in the PDAPP
transgene mouse model (31% and 45% reduction of
Ab1-x a tt h r e eh o u r sf o l l o w i n gas i n g l eo r a ld o s eo f1 0
mg/kg, and 30 mg/kg, respectively, data not shown) as
well as cortical Abx-40 in wild type FVB mice (Figures
5a, 6a, and 7a).
In acute single dose studies, ELN475516 lowered
brain Ab at three hours post treatment in a dose depen-
dent manner, effecting a 40% reduction at the lowest
dose tested (30 mg/kg), and up to a 71% reduction at
300 mg/kg (Figure 5a). A statistically significant reduc-
tion of thymic Hes-1 mRNA (an acute end-point of
Notch signaling inhibition) was detected at the highest
dose tested (300 mg/kg. Figure 5b). Terminal plasma
compound levels at the highest dose tested were 12.3
μM ,o ram o r et h a ns i x - f o l dm u l t i p l eo v e rt h ec e l l u l a r
IC50 for inhibition of Notch signaling. By comparison,
acute treatment with10 mg/kg of the non-selective GSI
LY411575 concomitantly lowered brain Ab (74%) and
thymic Hes-1 mRNA (60%) (Figure 5a, b, respectively).
The acute treatment study shown in Figure 5 provides a
benchmark for reduction of brain Ab in FVB mice trea-
ted with 30 mg/kg ELN475516 at three hours post dose.
To characterize the duration of efficacy in relation to
compound exposure at different doses for ELN475516,
we conducted a time course study in mice treated with
30, 100, and 300 mg/kg, and terminated at varying time
points following single dose. The results, shown in
Figure 6, indicate that Cmax was achieved at one hour
post dose (Figure 6b), maximal reduction of brain Ab
was observed at three hours post dose (Figure 6a), and
significant reduction was maintained at 10 hours post
dose at all doses tested (28%, 33%, and 56%, at 30, 100,
and 300 mg/kg, respectively). At 14 hours post dose, a
significant 14% and 29% reduction was observed in mice
treated with 100 and 300 mg/kg, with Ab levels return-
ing to baseline by 24 hours post dose in all treatment
groups. The results shown in Figure 6a suggest that
brain Ab was lowered by >25% for 24 hours per day in
mice dosed >300 mg/kg. Dose dependent increases in
brain and plasma exposure were seen in mice at the
three doses tested in this single dose study, where total
exposure in the 300 mg/kg group was 24X the 30 mg/
kg group, and 3X the 100 mg/kg group (Figure 6c).
To provide a critical test of improved in vitro selectiv-
ity in an in vivo context, we developed a seven-day
mouse safety model utilizing a b.i.d dosing regimen in
wild-type FVB mice. Mice treated with a non-selective
GSI (LY411575) at 5 mg/kg b.i.d. demonstrated 83%
reduction of brain Ab (Figure 7a). However, the reduc-
tion of brain Ab at this dose was accompanied by con-
comitant effects on endpoints related to Notch signaling
in peripheral organs. These effects included a decrease
Table 1 In-vitro Properties of Gamma-Secretase Inhibitors
Compound gamma:APP
IC50 (nM)
gamma:Notch
IC50 (nM)
enzyme selectivity
(APP/Notch)
SNC Ab EC50
(nM)
SNC Notch Signaling
EC50 (nM)
Cellular Selectivity
(APP/Notch)
L-685,458 0.63 (1) nd NA 13.2 ± 4.5 (4) 184 ± 145 (3) 14
LY411575 0.035 (1) 0.082 ± 0.008 (3) 2.4 0.116 ± 0.011
(3)
1.8 ± 1.35 (3) 16
ELN158162 650 14,000 21.5 nd nd NA
ELN318463 37.2 ± 18 (51) 1,889 ± 722 (3) 51 23.4 ± 8.6 (10) 2,818 ± 670 (10) 120
ELN475516 2.06 ± 0.35 (16) 29.81 ± 2.59 (4) 14.5 8.73 ± 3.96
(298)
719 ± 224.6 (298) 82
Potency For Inhibition Of App And Notch Processing by select gamma-secretase inhibitors in enzyme, as well as cellular assays described in text. The value in
parentheses next to each IC50 indicates the number of independent test occasions used to derive the IC50 value. Note: Cellular selectivity of L-685,458 was
determined prior to development of the SNC assay using different cellular assays for Ab production and Notch signaling.
Abbreviations: APP, amyloid precursor protein; SNC, a stable CHO cell line co-expressing APPSw, rat NotchΔE, and an NICD responsive CBF-Luciferase reporter
gene used to simultaneously assay inhibition of Ab production, and Notch signaling; Ab, amyloid beta-peptide.
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Page 9 of 21in body and thymus weight, increase in circulating neu-
trophils, goblet cell hyperplasia, plus elevated Math1
mRNA endpoints in duodenum and ileum indicative of
Notch signaling inhibition, as shown in Figure 7c, d,
Figure 8 and Figure 9c, d. Hence, the mouse seven-day
b.i.d. treatment model accurately reflects systemic
as well as target organ toxicities described for this
non-selective GSI, consistent with reports in other
models [28,29,75].
B a s e do nt h eo b s e r v e da c u t es a f e t ya n dp h a r m a c o k i -
netics (Figures 5 and 6), FVB mice were treated twice
daily with a range of oral doses of ELN475516 for seven
days as described in methods. The pharmacological and
safety end-points following this seven-day treatment are
shown in Figures 7, 8 and 9. Treatment of mice with
ELN475516 at the lowest dose tested (15 mg/kg/dose,
b.i.d.) resulted in a statistically significant 33% reduction
of brain Ab (at three hours post last dose), in close
agreement with the acute treatment study. The pharma-
cological effect of ELN475516 on brain Ab levels in FVB
mice was dose dependent, with maximal effect (74%
reduction) observed at >100 mg/kg, and exhibited a
clear pharmacokinetic/pharmacodynamic relationship in
which brain compound levels correlated inversely with
brain Ab levels (Figure 7b). In contrast with a statisti-
cally significant effect of the non-selective GSI
LY411575 on molecular Notch signaling endpoints
(Math-1 mRNA levels in duodenum and ileum, Figure
7c, d), systemic Notch target organ related endpoints
(thymus and small intestine weights relative to body
weight, Figure 8c, d), as well as systemic endpoints of
general toxicity (body weight, circulating neutrophils,
Figure 8a, b), ELN475516 had no significant effect rela-
tive to vehicle treated controls on these endpoints at all
doses tested.
We assessed cell homeostasis in the intestinal tract as
a more sensitive indicator of in vivo inhibition of Notch
signaling by gamma-secretase inhibitors. Goblet cell
hyperplasia was readily apparent in mice treated with
5 mg/kg of non-selective GSI LY411575 in both the
duodenum and ileum of the intestinal tract (Table 2,
Figure 9c and 9d), consistent with published observa-
tions [28,29,41,75]. Goblet cell hyperplasia was not
observed at any dose of ELN475516 in the duodenum.
In the ileum, although scattered minimal to mild goblet
cell hyperplasia was observed in a subset of animals
from some dose groups (Figure 9e-g), the changes in
goblet cell numbers observed were not dose-related.
The lack of effect on gastrointestinal tract cell homeos-
tasis in mice treated with up to 1,000 mg/kg/dose
ELN475516 b.i.d. is consistent with lack of effect on
molecular and systemic readouts of Notch signaling
shown in Figures 7 and 8. Terminal plasma levels of
compound in the lowest and highest treated dose were
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Figure 2 Novel sulfonamides exhibit properties in common
with classic gamma-secretase inhibitors. Western blots of cell
extracts (a) and media (b, c) after treatment of cultures in duplicate
of with gamma-secretase inhibitors indicated above the lanes.
Compounds were tested at two doses, approximately 1 X ED50 and
approximately 10 X ED50 based on cellular assay results. (a) Full
length and c-terminal fragments of APP total cellular lysates
recognized by an antibody against the C-terminus of APP (Sigma
A8717). The reference gamma-secretase inhibitors L-685,458 and
ELN46719 (analog of LY411575, see methods), as well as the novel
sulfonamides tested stabilize both a-CTF and b-CTF in a dose-
dependent manner, and none of the compounds significantly affect
steady-state levels of full-length APP. (b, c) Western blots of the
conditioned media samples from this same experiment probed with
antibody 8E5 against total secreted APP (b), and 192Sw against the
b-secreted APP formed by BACE cleavage of the Swedish mutant
APP over-expressed in these HEK293 cells (c). No significant effect
on either total sAPPa or sAPPb was seen by any of the gamma-
secretase inhibitors. (d) Quantification of Ab1-40 in the conditioned
media. The results suggest that the sulfonamide only affects
gamma-secretase cleavage of APP, and does not appear to have
nonspecific effects on overall APP metabolism or cell viability in
HEK293 cells.
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Page 10 of 21Figure 3 Binding site analysis by competitive displacement of biotinylated active site isostere. A competitive binding assay employing a
biotin conjugated active site isostere to capture gamma secretase from a partially purified cell extract, plus or minus co-incubation with
increasing concentrations of reference or test gamma secretase inhibitors, was developed to characterize inhibitor binding site. The eluted
enzyme captured on neutravidin beads was detected on western blots with antibodies recognizing either PS-1 amino-terminal fragment (PS1-
NTF), or Nicastrin (Nct). The binding assay was carried out using 50 nM affinity probe together with different concentrations of competing
compounds. Serial dilutions of affinity captured enzyme were included on the gels to provide a standard curve for densitometric quantitation of
test samples following autoradiography of the western blots. (a) The biotinylated isostere is displaced by its non-biotinylated analog L-685,458 in
a concentration dependent manner. In subsequent experiments, a 200-fold excess of L-685,458 was employed as a positive control. (b) LY411575
was tested for its ability to displace active site isostere at concentrations ranging up to 1000-fold its IC50 in the Gamma APP enzyme assay. There
is no significant displacement of the active site directed compound by at concentrations below 200-fold its IC50 in the enzyme assay. At higher
concentrations, a modest dose-dependent effect of LY411575 to displace the active-site-directed compound is observed on both Western blots.
Previous observations revealed substrate concentration affects the potency of sulfonamides in cell and enzyme assays (unpublished). Hence, the
ability of sulfonamides to displace the active site directed probe was tested in the absence (c and d, left side) or presence (c and d, right side)
of 1 Km substrate (MBP-C125sw). Substrate was added to enzyme concurrently with test compound and affinity ligand. In the presence of added
APP, the sulfonamides displace the active site probe in a dose-dependent manner. (c) No displacement of active site probe is observed by ELN-
318463 in the absence of substrate. In the presence of substrate, ELN318463 displaces approximately 50% of the active site probe at a
concentration of approximately 2,000-fold its IC50 in the Gamma APP assay. (d) ELN-475516 does not displace the active site probe at
concentrations ranging up to 2,000X its IC50 in the gammaAPP assay. However, in the presence of substrate, ELN475516 displaces 50% of the
active site probe at a concentration equivalent to approximately 67-fold its Gamma APP IC50. The results shown in (c) and (d) suggest
displacement of active site isostere from gamma-secretase by benzene caprolactam and fused pyrazolo-bicyclic sulfonamide is influenced by the
presence of substrate.
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Page 11 of 210.187 μM, and 12.3 μM, respectively. An in vivo selectiv-
ity of >65 for ELN475516 based on either dose or term-
inal plasma levels of compound is estimated, where
minimal efficacious dose is defined as ≥25% Ab reduction
in the brain at study termination (that is, three hours
post last dose), and the minimum toxic dose is defined as
the dose producing a statistically significant elevation of
Math1 mRNA levels. Hence, the in-vivo selectivity of
ELN475516 corroborates the improved biochemical as
well as cellular selectivity for inhibition of Ab production
from APP by gamma-secretase, compared with inhibition
of Notch processing and Notch signaling. Limiting N-
glucuronidation precluded longer-term studies with
ELN475516 in mice (or other models). However,
ELND006, a lead optimized analog derived from
ELN475516, was well tolerated for three and six months
in a chronic PDAPP mouse study at doses which affected
AD pathology in the absence of any toxicity [76].
Discussion
To discover novel APP-selective inhibitors of gamma-
secretase, we developed cell-free assays employing
recombinant APP or Notch substrates incubated with
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Figure 4 Acute reduction of brain Ab by ELN318463 in PDAPP
(a) and FVB mice (b). The mice were dosed orally with vehicle, or
ELN318463 at 30 mg/kg or 100 mg/kg and sacrificed 3 h post
treatment. Brain Ab1-x in PDAPP (a), or Abx-40 in FVB (b) was
quantified by ELISA following extraction in guanidine buffer as
described in methods. ** denotes P < 0.01, *** denotes P < 0.001
by Mann-Whitney in A, and two-tailed Students t-test in (b).
Figure 5 Reduction of brain Ab and thymic Hes-1 in wild-type
FVB mice after treatment with gamma-secretase inhibitor.
Female FVB mice were treated orally with a single dose of
ELN475516 (30, 100 or 300 mg/kg), LY411575 (10 mg/kg) or vehicle
and sacrificed at three hours post dose. (a) Cortical Abx-40 levels,
estimated by ELISA from guanidine extracted brain homogenates.
(b) Thymic Hes-1 mRNA levels, estimated by TaqMan RT-PCR.
Statistical significance between treatment groups and vehicle was
determined by ANOVA and Dunnett’s test. *** P < 0.001, * P < 0.05
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Page 12 of 21an enriched enzyme preparation derived from IMR-32
neuroblastoma cells. We utilized this biochemical assay
for APP cleavage by gamma-secretase in a high-through-
put screen of a chemical library and discovered amino-
caprolactam sulfonamide leads, which demonstrated
APP-selective inhibition of gamma-secretase activity in
vitro. The selectivity of our lead series was confirmed in
a cellular assay. Comparison of APP selectivity of non-
selective reference GSIs in cell-free compared with cel-
lular (SNC) assay reveals a basal 15-22X right-ward shift
for selectivity in the cellular assay compared with the
cell-free assay with reference non-selective GSI’s
L-685,458 and LY411575. This observed shift in selectiv-
ity between a cell-free assay which measures inhibition
of substrate cleavage, versus downstream signaling
events, likely reflects a difference between inhibition of
Notch cleavage vs. Notch signaling. Our observation is
consistent with findings that Notch signaling was only
reduced 35 to 48% in cells treated with concentrations
of peptidomimetic GSIs which abolished NICD forma-
tion to below detectable levels [77].
The benzene caprolactam sulfonamide ELN381463
[59] lowered brain Ab1-X in a concentration dependent
manner in PDAPP mice; however, reduction of Abx-40
was nominal and did not exhibit a concentration depen-
dent effect in two mouse lines tested (PDAPP and FVB).
This discordance in a concentration effect on reduction
of brain Ab species cannot be explained by differences
in drug levels in the two mouse lines, nor by assay dif-
ferences, as discussed above. We are not able to explain
the basis for this discrepancy; however, our observation
suggests efficacy determination of GSI’s in AD transgene
models should be corroborated in wild type mice (see
also Discussion below).
Lead optimization of the caprolactam sulfonamide
enabled discovery of a novel pyrazolylazabicyclo(3.3.1)
nonane sulfonamide, ELN475516 (this report, and [60]).
ELN475516 demonstrated equipotent in vivo activity
against Ab1-X in PDAPP transgene as well as Abx-40 in
wild type mice, retaining favorable 123X APP-selective
inhibition of gamma-secretase. The potency and cellular
selectivity of ELN475516 compares favorably with
recently disclosed GSI-953 [48] and BMS-708163
[78,79], which demonstrated 45X and 57X selectivity in
our hands, with IC50 values for inhibition of Ab produc-
tion in the SNC assay of 8.0 nM, and 1.13 nM, respec-
tively. The novel sulfonamide inhibitors we describe
exhibit all the signatures associated classical gamma-
secretase inhibitors: elevation of C99 levels and equipo-
tent inhibition of Ab40 and Ab42 production without
affecting secreted APP levels. These properties are con-
sistent with those reported for a novel thiophene sulfo-
namide gamma-secretase inhibitor, GSI-953 [48]. In
binding site studies, both ELN318463 and ELN475516
were not able to displace a biotin-labeled active site
binding probe in cellular extracts over a range of con-
centrations tested, suggesting the inhibitors bind
gamma-secretase at a site distinct from the active site,
Figure 6 Time course of brain Ab r e d u c t i o ni nw i l d t y p eF V B
mice after treatment with a single dose of ELN475516. Female
FVB mice were treated orally with a single dose of ELN475516 (30,
100 or 300 mg/kg, n = 5/dose group) or vehicle and sacrificed at 1,
3, 6, 10, 14 and 24 hours post dose. (a) Cortical Abx-40 levels,
estimated by ELISA from guanidine extracted brain homogenates.
(b) ELN475516 levels in plasma and brain estimated by LC/MS/MS.
(c) ELN475516 plasma and brain exposure over 24 hours (AUC0-24).
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as non-transition state-based gamma-secretase inhibitors
[80]. Interestingly, in the presence of exogenous APP
substrate added to the extracts, we were able to detect
displacement of the active site isostere at concentrations
above the IC50 for Ab inhibition by the compound. This
novel observation suggests that occupancy of the sub-
strate binding site on gamma-secretase by APP induces
a conformational change bringing the sulfonamide bind-
ing site and isostere binding (that is, catalytic) sites in
close proximity, enabling displacement of isostere by
sulfonamide at supra-physiological concentrations.
Although we did not test the effect of other substrates
in the competitive displacement assay, it will be
interesting to compare the effect, for example, of Notch
substrate on displacement of active site isostere by test
GSI’s in future studies.
The improved selectivity of ELN475516 was tested in
a mouse seven-day repeat dose model. Relative to
LY411575, a reference non-selective gamma-secretase
inhibitor, ELN475516 demonstrated significant reduc-
tion of brain Ab at the lowest dose tested (15 mg/kg/
dose, b.i.d.), with no overt signs of toxicity at the high-
est dose tested (1,000 mg/kg/dose, b.i.d.) at the end of
the study, indicating an in vivo selectivity >65 based
on dose as well as terminal compound concentration
in plasma. For this study, a minimum efficacious dose
was defined as that dose effecting >25% reduction at
Figure 7 Reduction of Ab and Math1 in FVB mice after treatment with ELN475516 or LY411575 for seven days. Female FVB mice were
treated orally twice daily with ELN475516, LY411575 or vehicle and sacrificed at three hours post last dose. (a) Cortical Abx-40 levels, estimated
by ELISA from guanidine brain homogenates. Statistically significant (P <.0001) Ab reduction (33%) was achieved at the lowest dose tested (15 mg/
kg/dose). (b) Relationship of ELN475516 levels in plasma (estimated by LC/MS/MS) vs. brain Abx-40 levels (estimated by ELISA from guanidine brain
homogenates). Duodeneum (c) and Ileum (d) Math1 mRNA levels, estimated by TaqMan RT-PCR. Treatment with 5 mg/kg/dose LY411575 BID for
seven days resulted in a robust elevation of Math1 gene expression in the duodeneum and ileum (P < 0.001). No effects on Math1 in the
duodeneum or ileum were observed after treatment of ELN475516 BID for seven days up to the highest dose tested, 1,000 mg/kg/dose (2,000 mg/
kg/day). Statistical significance between treatment groups and vehicle was determined by ANOVA and Dunnett’s test. ***, P < 0.001
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Page 14 of 21study termination (that is, three hours post last dose).
Terminal plasma compound levels at the highest dose
tested were 12.3 μM, a 17-fold multiple over the cellu-
lar IC50 for inhibition of Notch signaling. The utility of
the mouse as a model for screening of lead gamma-
secretase inhibitor candidates against Notch endpoints
has been previously described [41]. Our studies
employed the wild-type FVB strain of mice for Ab and
Notch endpoints instead of transgenic AD mice as
described by Hyde et al. to avoid potential transgene
model specific influences on in vivo inhibitor potency
against Ab endpoints. For example, substrate expression
levels [81], as well as PS1 FAD mutations [59,82-84]
have been demonstrated to effect a right-ward shift on
in vitro potencies of gamma-secretase inhibitors. If sub-
strate levels, or PS1 isoform contributes to in vivo
potency shifts, the effect could potentially confound
estimates of in vivo selectivity in an APP and/or
PS1FAD transgene mouse model. Consistent with the
influence of APP expression levels on inhibitor potency,
we observed a 33% reduction of brain Abx-40 in wt FVB
mice at three hours post treatment with 30 mg/kg GSI-
953, compared with 5 mg/kg producing a similar magni-
tude effect in Tg2567 mice [48], although it is possible
t h eo b s e r v e dd i s c r e p a n c ym a yb ea c c o u n t e df o rb yd i f -
f e r e n c e si nd r u ge x p o s u r e si nt h et a r g e to r g a ni nF V B
mice and Tg2576, or different species of Ab assayed in
t h ed i f f e r e n tm o u s em o d e l sq u e r i e d .
Figure 8 Assessment of systemic safety signals in FVB mice after treatment with ELN475516 or LY411575 for seven days.F e m a l eF V B
mice were treated orally twice daily with ELN475516, LY411575 or vehicle and sacrificed at three hours post last dose. Mice treated with 5 mg/
kg LY411575 BID for seven days showed consistent signs of toxicity while there were no observed signs of toxicity in any group treated with
ELN475516, even up to the highest dose of 1000 mg/kg (2000 mg/kg/day) for seven days. (a) Body weight (b) Neutrophils (c) Relative thymus
weight and (d) Relative small intestine weight. Statistical significance between treatment groups and vehicle was determined by ANOVA and
Dunnett’s test. *** P <0.001, ** P < 0.01.
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Page 15 of 21Figure 9 Photomicrographs of ileum sections (10X magnification) from mice treated seven days x b.i.d. with gamma-secretase
inhibitors noted below. Selected sections represent the range of goblet cell hyperplasia observed in this study. In H&E stained sections (a, c, e
and g), goblet cells appear as cells with clear or foamy cytoplasm (arrows) while in PAS stained sections (b, d, f and h) they appear as dark
magenta stained cells (arrow heads). A normal population of goblet cells was observed in all vehicle control mice (a, b). All positive control
LY411575 treated mice had a moderate increase in goblet cells (c, d). There was no apparent dose-related increase in goblet cells across
ELN475516 treated groups (see Table 2); among all mice in these groups, 21 had no increase in goblet cells, 8 had a questionable increase
(illustrated by a single animal from 100 mg/kg dose group g, h). A single mouse from the 600 mg/kg dose group had a mild increase in goblet
cells, which is shown for comparison purposes in panels (e and f). Scale bar = 100 μm.
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GSIs described to date are based on sulfonamide phar-
macophore ([47,79,85-87], and this report). Indeed, a first
generation aryl sulfonamide GSI, BMS299897 [10,11,88],
was demonstrated to avoid Notch inhibition endpoints in
the gastro-intestinal tract in a preclinical safety model
[28]. Additional arylsulfonamide analogs related to
BMS299897 [89], as well as aminocaprolactam sulfona-
mides related to ELN318463 have been described [79,90].
The APP selectivity of the sulfonamide core appears to
be very sensitive to structural modifications. For example,
potent and in vivo active (bicycle(4:2:1) nonane sulfamide
GSI’s [91,92], as well as 4-cyclohexyl sulfones [12,93]
have been reported as equipotent on APP and Notch.
Interestingly, despite equipotent inhibition of APP and
Notch processing by gamma-secretase, sulfones are
reported to be well tolerated at 3 mg/kg dose in a three-
month treatment study in the Tg2576 mouse model [14],
although higher doses were not reported. In a similar
vein, whereas potent piperdine containing sulfonamide
GSI have also been described [90,94-97], APP selectivity
has only been reported following incorporation of a pyra-
zole substituent into the piperdine sulfonamide core [98].
The molecular basis of sulfonamide based GSIs APP
selectivity remains to be fully elucidated. We have
reported that one contributor of selectivity may be the
more potent inhibition of PS1 gamma-secretase com-
pared with PS2 gamma-secretase [59] by sulfonamides.
Consistent with this finding, ELN475516 is a five-fold
more selective PS1 gamma-secretase inhibitor relative to
PS2 gamma-secretase (unpublished). Site directed muta-
genesis studies have identified select residues in PS1
which affect AICD processing from APP without affect-
ing NICD production from Notch [99,100], supporting
the potential for modulating cleavage by this enzyme in
a selective manner. These observations, combined with
substituted cysteine accessibility mutagenesis to more
precisely map inhibitor binding residues [101,102], offer
an avenue to further characterize the biochemical basis
of APP selectivity. In summary, the in vivo selectivity of
ELN475516 from a mouse seven-day safety model cor-
roborates the improved selectivity estimated for this
compound in the cellular SNC assay, confirming APP
selective inhibition of gamma-secretase in vivo by this
novel pyrazolylazabicyclo(3.3.1)nonane sulfonamide.
ELN475156 represents a validated foundation for further
lead optimization to discover APP selective second gen-
eration GSIs with improved safety and drug like proper-
ties suitable for chronic AD therapy [60,98,103,104].
Conclusions
Our results showing discordance in reduction of brain
Ab between PDAPP and wild-type FVB mice following
treatment with ELN318463 highlight the importance of
evaluating GSI’s for potency and selectivity in non-trans-
gene models of Alzheimer’sd i s e a s e .T h ein vitro and
in vivo selectivity of ELN475516 demonstrates that dis-
covery of APP selective GSI’s is feasible, and that APP
selective GSI’s offer potentially safer candidates as thera-
peutics for Alzheimer’s disease.
Additional material
Additional File 1: Figure S1. In vitro enzyme kinetics of gamma-
secretase preparation on APP and Notch substrates. The results show
that the in vitro assay displays Michaelis-Menten kinetics for substrate.
Additional File 2: Figure S2. Neo-epitope specificity of Notch
antibody recognizing Notch Intracellular domain.
Additional File 3: Figure S3. Equipotent inhibition of Ab40 and
Ab42 by gamma-secretase inhibitors in a cellular assay.
Additional File 4: Figure S4. Flow-chart of displacement assay with
active-site binding affinity ligand in the presence or absence of
added APP substrate plus competing sulfonamide.
Additional File 5: Figure S5. Evolution of sulfonamide structure
activity relationship from caprolactam sulfonamides to fused bi-
cyclic sulfonamides.
Table 2 Histology scores of mice following 7 days treatment
Treatment (mg/kg/dose) Duodenum Ileum
# animals affected Mean severity score # animals affected Mean severity score
Vehicle 0 NA 0 NA
5 mg/kg LY411575 4* 2 5 3
15 mg/kg ELN475516 0 NA 0 NA
30 mg/kg ELN475516 0 NA 4 0.5
100 mg/kg ELN475516 0 NA 2 1.25
300 mg/kg ELN475516 0 NA 0 NA
600 mg/kg ELN475516 0 NA 2 0.5
1,000 mg/kg ELN475516 0 NA 1 0.5
Small intestine histopathology of mice treated twice daily with the compound and doses indicated in column 1. Duodenum and ileum segments from treated
mice were analyzed for cellular homeostasis by histology as indicated in methods. The number of animals affected is indicated next to the dose, as well as the
mean severity score for goblet cell hyperplasia in the affected animals. Severity score rating: 0 = no significant change, 0.5 = questionable, 1 = minimal, 2 = mild,
3 = moderate, 4 = severe (*tissue lost from one animal). NA indicates not applicable.
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Page 17 of 21Abbreviations
Aβ: amyloid beta-peptide; AD: Alzheimer’s disease; APP: amyloid precursor
protein; APPsw: Swedish familial Alzheimer’s disease mutant isoform of APP:
BACE: beta-APP cleaving enzyme; BMS299897: 2-((1R)-1-(((4-chlorophenyl)
sulfonyl)(2,5-difluorophenyl)amino)ethyl)-5-fluorobenzenebutanoic acid; CHES:
2-(N-Cyclohexylamino)ethanesulfonic acid; CHO: Chinese hamster ovary; CSF:
cerebrospinal fluid; CTF: carboxy-terminal fragment; DTT: dithiothreitol;
DMSO: dimethyl-sulfoxide; ELISA: enzyme like immunoadsorbent assay;
ELN158162: 4-Chloro-N-(3-methoxy-4-(2-(4-methyl-1,3-thiazol-5-yl)ethoxy)
benzyl)-N-((3R)-2-oxoazepan-3-yl)benzenesulfonamide; ELN-318463: N-(4-
Bromobenzyl)-4-chloro-N-((3R)-2-oxoazepan-3-yl)benzenesulfonamide; ELN-
475516: 10-((4-Chlorophenyl)sulfonyl)-4,5,6,7,8,9-hexahydro-1H-4,8-
epiminocycloocta(c)pyrazole; FAD: familial Alzheimer’s disease; GSI: gamma-
secretase inhibitor; HA: hemagglutnin antigen; H&E, hematoxylin and eosin;
HEK, human embryonic kidney; Hes, hairy enhancer-of-split; HTS: high
through-put screen; KO: knock-out,; L-685,458: tert-Butyl (2S,3R,5R)-6-((S)-1-
((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-4-methyl-1-oxopentan-2-
ylamino)-5-benzyl-3-hydroxy-6-oxo-1-phenylhexan-2-ylcarbamate; LC: liquid
chromatography; mAb: monoclonal antibody; LY 411575, (S)-2-((S)-2-(3,5-
Difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-
dibenzo(b,d)azepin-7-yl)propanamide; MES, 2(N-Morpholino)ethanesulfonic
acid; Math: mouse atonal homolog; MS: mass spectrometry; Nct: Nicastrin;
NICD: Notch Intracellular domain; PAGE: polyacrylamide gel electrophoresis;
PAS: periodic acid-Schiff stain; PDAPP: platelet derived growth factor
promoter driven AD transgene mouse; sAPP: secreted APP; sAPPβ: secreted
APP product of BACE cleavage; SNC: a stable CHO cell line co-expressing
APPSw, rat NotchΔE, and an NICD responsive CBF-Luciferase reporter gene;
PS: presenilin; RT-PCR: reverse-transcriptase polymerase chain reaction; WGA:
wheat-germ agglutnin.
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